The Global Palonosetron Hydrochloride API Market was valued at USD 722 Million in 2024 and is projected to reach USD 1,144 Million by 2032, growing at a Compound Annual Growth Rate (CAGR) of 6.9% during the forecast period (2024–2032). This growth is being driven by rising cancer incidence worldwide with over 20 million new cases annually, expanding chemotherapy regimens, and increasing demand for effective antiemetic solutions to combat chemotherapy-induced nausea and vomiting (CINV) across oncology and postoperative care sectors.

As the pharmaceutical industry advances toward more precise and patient-centric oncology treatments, the focus turns to key API manufacturers who are pioneering high-purity production, regulatory compliance, and innovative synthesis processes. In this blog, we profile the Top 10 Companies in the Palonosetron Hydrochloride API Industry—a mix of global pharma giants, specialized API producers, and emerging innovators shaping the future of anti-nausea therapeutics.

---

🔟 1. Midas Pharma

Headquarters: Germany
Key Offering: High-purity Palonosetron Hydrochloride API, GMP-certified grades for injection formulations

Midas Pharma has established itself as a reliable European supplier of Palonosetron Hydrochloride API, focusing on stringent EDQM certification and quality assurance for oncology supportive care. The company supplies to major pharmaceutical formulators across Europe, emphasizing impurity control below parts-per-billion levels to meet evolving regulatory demands. Their expertise in handling complex chiral synthesis positions them strongly in the high-purity segment.

Production Excellence Initiatives:

• EDQM certification for dedicated Palonosetron facility
• Advanced purification technologies for genotoxic impurity reduction
• Strategic partnerships with EU oncology drug developers

Download FREE Sample Report: Palonosetron Hydrochloride API Market – View in Detailed Research Report

---

9️⃣ 2. Qilu Pharmaceutical Co Ltd

Headquarters: China
Key Offering: Palonosetron Hydrochloride API, ≥99% purity for CINV prevention drugs

Qilu Pharmaceutical stands out with its patented crystallization process achieving 99.9% purity levels for Palonosetron Hydrochloride API. Serving global markets, the company exports to North America and Europe while supporting domestic demand in Asia’s growing oncology sector. Their scale enables competitive pricing without compromising on FDA and EMA compliance.

Production Excellence Initiatives:

• Patented high-purity crystallization technology
• Capacity expansions for 5-HT3 antagonist APIs
• Green chemistry integration to reduce solvent waste

---

8️⃣ 3. Emcure Pharmaceuticals Ltd

Headquarters: India
Key Offering: Palonosetron Hydrochloride API for generic antiemetics, powder and solution forms

Emcure Pharmaceuticals contributes significantly to the Indian API landscape, producing Palonosetron Hydrochloride for both domestic and export markets. With a focus on cost-effective synthesis, they cater to injection and oral formulations used in postoperative nausea prevention, benefiting from India’s regulatory approvals and expanding cancer care infrastructure.

Production Excellence Initiatives:

• Optimized synthesis routes for cost efficiency
• Compliance with USFDA and WHO-GMP standards
• Investments in continuous manufacturing pilots

---

7️⃣ 4. Cipla Ltd

Headquarters: India
Key Offering: Palonosetron Hydrochloride API, high-grade for combination antiemetic therapies

Cipla Ltd is a powerhouse in affordable API production, supplying Palonosetron Hydrochloride to support global generic drug makers. Their vertically integrated facilities ensure reliable supply for CINV treatments, with recent expansions targeting emerging markets where chemotherapy access is rising rapidly.

Production Excellence Initiatives:

• Enhanced capacity for oncology supportive APIs
• Rigorous impurity profiling and stability testing
• Collaborations for novel formulation development

Download FREE Sample Report: Palonosetron Hydrochloride API Market – View in Detailed Research Report

---

6️⃣ 5. Tyche Industries Ltd

Headquarters: India
Key Offering: Cost-optimized Palonosetron Hydrochloride API, chiral synthesis expertise

Tyche Industries differentiates through a proprietary synthetic route that cuts production costs by about 18%, making high-quality Palonosetron API accessible for generic manufacturers. They focus on chiral purity critical for this 5-HT3 antagonist, serving pharmaceutical companies in regulated and emerging markets alike.

Production Excellence Initiatives:

• Cost-effective synthetic pathway innovations
• High-yield crystallization for ≥99.5% purity
• Sustainability-focused waste reduction strategies

---

5️⃣ 6. Seqens

Headquarters: France
Key Offering: Palonosetron Hydrochloride API for oncology and postoperative applications

Seqens has bolstered its position through strategic acquisitions, enhancing its oncology API portfolio including Palonosetron Hydrochloride. As a CDMO leader, they provide end-to-end services from synthesis to regulatory filing, appealing to global pharma firms seeking reliable high-purity supplies.

Production Excellence Initiatives:

• Post-acquisition capacity boosts in US facilities
• Advanced analytical methods for compliance
• Focus on combination therapy API grades

---

4️⃣ 7. Century Pharmaceuticals

Headquarters: India
Key Offering: Palonosetron Hydrochloride API tailored for injection and powder forms

Century Pharmaceuticals excels in specialized API production for antiemetics, with Palonosetron Hydrochloride forming a core part of their oncology lineup. Their facilities meet international GMP standards, supporting exports to regions with high CINV treatment needs.

Production Excellence Initiatives:

• Specialized oncology API production lines
• Quality enhancements via continuous processing
• Supply chain diversification for raw materials

---

3️⃣ 8. Aurobindo Pharma

Headquarters: India
Key Offering: Palonosetron Hydrochloride API, FDA-approved high-volume production

Aurobindo Pharma leverages its expansive API infrastructure to produce Palonosetron Hydrochloride at scale, capitalizing on increasing FDA approvals. They serve major markets with consistent quality, aiding the shift to generic antiemetics amid patent cliffs.

Production Excellence Initiatives:

• Multiple FDA-inspected facilities
• Capacity scaling for Asia-Pacific demand
• Process optimizations for margin protection

---

2️⃣ 9. Dr. Reddy’s Laboratories Ltd

Headquarters: India
Key Offering: Premium Palonosetron Hydrochloride API for global formulations

Dr. Reddy’s Laboratories announced a $50 million expansion in 2023 targeting 5-HT3 antagonists like Palonosetron Hydrochloride, strengthening their leadership in generics. Their competitive costs and quality drive supplies to North America and Europe.

Production Excellence Initiatives:

• $50M capacity expansion for antiemetics
• Advanced R&D in synthesis efficiency
• Strategic FDA approvals for new sites

---

1️⃣ 10. Teva Pharmaceutical Industries Ltd

Headquarters: Israel
Key Offering: Vertically integrated Palonosetron Hydrochloride API, comprehensive grades

Teva Pharmaceutical Industries Ltd dominates with its integrated supply chain, generating significant revenue from antiemetic APIs including Palonosetron Hydrochloride. Their global distribution supports widespread CINV management, backed by $4.2 billion in API division sales in 2023.

Production Excellence Initiatives:

• Vertically integrated global production
• Expansive R&D for formulation compatibility
• Leadership in high-volume, high-purity supply

Read Full Report: Palonosetron Hydrochloride API Market – View in Detailed Research Report

---

🌍 Outlook: The Future of Palonosetron Hydrochloride API Is Efficient, Compliant, and Accessible

The Palonosetron Hydrochloride API market is evolving rapidly. While high-purity grades lead in regulated markets, investments in process optimization, continuous manufacturing, and emerging economy expansions are reshaping supply dynamics.

📈 Key Trends Shaping the Market:

• Rising adoption of continuous manufacturing for 15-20% yield improvements
• Regulatory expansions for pediatric and highly emetogenic uses
• Growth in Asia-Pacific at 8.2% CAGR through 2032
• Shift to green synthesis amid environmental pressures

Read Full Report: Palonosetron Hydrochloride API Market – View in Detailed Research Report

The companies listed above are not only supplying critical APIs for nausea control—they’re spearheading the next era of oncology supportive care.